The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

January 12, 2024

Study Completion Date

January 12, 2024

Conditions

Advanced Solid Tumors

Interventions

DRUG

HX301

At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg

Trial Locations (1)

National center/cancer hospital,chinese Academy of Medical Sciences and Peking Union Medicial College, Beijing